5:35 PM
 | 
Jul 01, 2013
 |  BC Extra  |  Clinical News

Alnylam reports Phase II data for amyloidosis compound

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented interim data from an open-label Phase II trial evaluating ALN-TTR02 to treat transthyretin (TTR)-mediated amyloidosis. In 19 evaluable patients, multiple doses of IV ALN-TTR02 led to rapid,...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >